ImpactRx gobbles up TargetRx

ImpactRx, which measures the impact of promotion on prescriber behavior, said it acquired 100% of TargetRx, a pharma sales and marketing effectiveness firm. 

Terms were not disclosed, but a source familiar with the transaction estimated its size at $5-10 million.

Known as ImpactRx, the combined company will be led by new ImpactRx president and CEO Gregory Ellis, who recently replaced Richard Altus in that role. (See p. 55 for a profile.)

Since 1999, TargetRx has been providing pharma and biotech companies with insight into the drivers of both product choice and brand adoption. But it had struggled in the last year from customer and employee turnover. 

ImpactRx is part of private equity firm Symphony Technology Group, which in April acquired a majority interest for an undisclosed sum. Merck Capital Ventures, the venture capital arm of Merck, also maintains a stake.

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.